Liposomal encapsulated anti-cancer drugs.
Among several drug delivery systems, liposomal encapsulated anti-cancer agents represent an advanced and versatile technology. Several formulations of liposomal anthracyclines are approved, e.g. for the treatment of metastatic breast cancer (pegylated and non-pegylated liposomal doxorubicin) or AIDS-related Kaposi's sarcoma (pegylated liposomal doxorubicin and liposomal daunorubicin). Meanwhile, virtually all anti-cancer drugs have been encapsulated in liposomes using different technologies. This review will summarize preclinical and clinical data of approved and exemplary emerging liposomal anti-cancer agents.
Hofheinz
Ralf-Dieter
RD
Onkologisches Zentrum, III. Medizinische Klinik, Fakultät für Klinische Medizin Mannheim, Universität Heidelberg, Mannheim, Germany. ralf.hofheinz@med3.uni-heidelberg.de
Gnad-Vogt
Senta Ulrike
SU
Beyer
Ulrich
U
Hochhaus
Andreas
A
D000818:Animals; D018943:Anthracyclines / Q000008:administration & dosage / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D009202:Cardiomyopathies / Q000139:chemically induced; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage; D006801:Humans; D008081:Liposomes; D009369:Neoplasms / Q000188:drug therapy*; D017671:Platinum Compounds / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D018943:Anthracyclines; D000970:Antineoplastic Agents; D008081:Liposomes; D017671:Platinum Compounds; D003561:Cytarabine; D014750:Vincristine; D002166:Camptothecin